[
  {
    "ts": null,
    "headline": "Merck (MRK) Outpaces Stock Market Gains: What You Should Know",
    "summary": "Merck (MRK) concluded the recent trading session at $85.11, signifying a +1.28% move from its prior day's close.",
    "url": "https://finnhub.io/api/news?id=e06bfb128e27413616856d1b21d5375f5d335092e1bd916452059ab43dc9b584",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757630704,
      "headline": "Merck (MRK) Outpaces Stock Market Gains: What You Should Know",
      "id": 136711331,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) concluded the recent trading session at $85.11, signifying a +1.28% move from its prior day's close.",
      "url": "https://finnhub.io/api/news?id=e06bfb128e27413616856d1b21d5375f5d335092e1bd916452059ab43dc9b584"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Announces Positive Phase 3 Results For 21-Valent Pneumococcal Vaccine",
    "summary": "Merck (MRK) recently showcased significant advancements by unveiling positive results from its Phase 3 STRIDE-13 Trial of the CAPVAXIVE vaccine, signaling progress in vaccine innovation. Over the past month, Merck's stock price increased by 5%, a period marked by several positive scientific and financial updates. This was in line with the buoyant market, which also saw a broad climb, driven by overall positive economic data and expectations of interest rate cuts. Additionally, announcements...",
    "url": "https://finnhub.io/api/news?id=31c959a7d1769c890ae9696e1c16a30605ce393a928f00c7300cf58b34701085",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757616158,
      "headline": "Merck (MRK) Announces Positive Phase 3 Results For 21-Valent Pneumococcal Vaccine",
      "id": 136703964,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) recently showcased significant advancements by unveiling positive results from its Phase 3 STRIDE-13 Trial of the CAPVAXIVE vaccine, signaling progress in vaccine innovation. Over the past month, Merck's stock price increased by 5%, a period marked by several positive scientific and financial updates. This was in line with the buoyant market, which also saw a broad climb, driven by overall positive economic data and expectations of interest rate cuts. Additionally, announcements...",
      "url": "https://finnhub.io/api/news?id=31c959a7d1769c890ae9696e1c16a30605ce393a928f00c7300cf58b34701085"
    }
  },
  {
    "ts": null,
    "headline": "MSD calls off £1bn UK expansion amid government-big pharma tensions",
    "summary": "The US-based pharma has scrapped its UK expansion plans due to the government's lack of investment in the life sciences sector.",
    "url": "https://finnhub.io/api/news?id=dcc1fbf00e6b08f2c54c2beae25c68b3984901dcc95390e2441be899d6fca063",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757615284,
      "headline": "MSD calls off £1bn UK expansion amid government-big pharma tensions",
      "id": 136703965,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The US-based pharma has scrapped its UK expansion plans due to the government's lack of investment in the life sciences sector.",
      "url": "https://finnhub.io/api/news?id=dcc1fbf00e6b08f2c54c2beae25c68b3984901dcc95390e2441be899d6fca063"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on U.K. pharmaceutical research-and-development investment, Novo Nordisk and more in the latest Market Talks covering Health Care.",
    "url": "https://finnhub.io/api/news?id=ef7a050331c2ca6389ced9823715b5e446e5369d7cf6798d4112e2de80da3dc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757611740,
      "headline": "Health Care Roundup: Market Talk",
      "id": 136703966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Find insight on U.K. pharmaceutical research-and-development investment, Novo Nordisk and more in the latest Market Talks covering Health Care.",
      "url": "https://finnhub.io/api/news?id=ef7a050331c2ca6389ced9823715b5e446e5369d7cf6798d4112e2de80da3dc9"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=23bf5ed9cfb31f7aec34fd7575d063b1ee2fef5feefc4f9459b31f09c045bafc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757608440,
      "headline": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "id": 136713847,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Thursday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=23bf5ed9cfb31f7aec34fd7575d063b1ee2fef5feefc4f9459b31f09c045bafc"
    }
  },
  {
    "ts": null,
    "headline": "Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?",
    "summary": "Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.",
    "url": "https://finnhub.io/api/news?id=49dd5b5a41f429031b112062424bbb1efbb4dc2d73993961d43ca2a4c3376770",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757603100,
      "headline": "Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?",
      "id": 136703967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.",
      "url": "https://finnhub.io/api/news?id=49dd5b5a41f429031b112062424bbb1efbb4dc2d73993961d43ca2a4c3376770"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?",
    "summary": "Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.",
    "url": "https://finnhub.io/api/news?id=9669bff4514160679c21a58eabf9ea41b22c74336b030d59e04723c053de416d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757602320,
      "headline": "Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?",
      "id": 136703968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.",
      "url": "https://finnhub.io/api/news?id=9669bff4514160679c21a58eabf9ea41b22c74336b030d59e04723c053de416d"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister",
    "summary": "The Conservatives said Merck’s decision should send alarm bells ringing across Government.",
    "url": "https://finnhub.io/api/news?id=3b8ce3d9126c8e8ec7320ffaebcdf403cc216683765144dd3dee2dd187b1adb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757595608,
      "headline": "Merck’s move to axe £1bn UK expansion was ‘commercial decision’, says minister",
      "id": 136703969,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Conservatives said Merck’s decision should send alarm bells ringing across Government.",
      "url": "https://finnhub.io/api/news?id=3b8ce3d9126c8e8ec7320ffaebcdf403cc216683765144dd3dee2dd187b1adb0"
    }
  },
  {
    "ts": null,
    "headline": "CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease",
    "summary": "RAHWAY, N.J., September 11, 2025--CAPVAXIVE Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease",
    "url": "https://finnhub.io/api/news?id=4d0b801edbd8d32f72ed4e340ae04cb925c58ff1696ff07008e43606b3dbbab0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757591100,
      "headline": "CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease",
      "id": 136703970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., September 11, 2025--CAPVAXIVE Demonstrates Positive Immune Responses in Children and Adolescents at Increased Risk of Pneumococcal Disease",
      "url": "https://finnhub.io/api/news?id=4d0b801edbd8d32f72ed4e340ae04cb925c58ff1696ff07008e43606b3dbbab0"
    }
  },
  {
    "ts": null,
    "headline": "Britain defends investment record as Merck scraps labs over pharma environment",
    "summary": "LONDON (Reuters) -Britain defended its record on attracting investment on Thursday after U.S. drugmaker Merck said it was abandoning a new London research centre and a top industry lobby group warned a challenging business environment was hurting the sector.  Merck had already started building new laboratories near Kings Cross in central London ahead of an expected 2027 opening, but said late on Wednesday it was walking away from the site.  The news has added to a sense of anxiety around Britain's life sciences sector after the country's biggest drugmaker AstraZeneca scrapped plans for a new UK vaccine plant, and the government became caught up in a row over drug pricing.",
    "url": "https://finnhub.io/api/news?id=980329dae33ff6ded7af0ddbad7cca5aa7f12e4e1daec90424e1aaf980a766cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757587358,
      "headline": "Britain defends investment record as Merck scraps labs over pharma environment",
      "id": 136703971,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "LONDON (Reuters) -Britain defended its record on attracting investment on Thursday after U.S. drugmaker Merck said it was abandoning a new London research centre and a top industry lobby group warned a challenging business environment was hurting the sector.  Merck had already started building new laboratories near Kings Cross in central London ahead of an expected 2027 opening, but said late on Wednesday it was walking away from the site.  The news has added to a sense of anxiety around Britain's life sciences sector after the country's biggest drugmaker AstraZeneca scrapped plans for a new UK vaccine plant, and the government became caught up in a row over drug pricing.",
      "url": "https://finnhub.io/api/news?id=980329dae33ff6ded7af0ddbad7cca5aa7f12e4e1daec90424e1aaf980a766cf"
    }
  },
  {
    "ts": null,
    "headline": "Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley",
    "summary": "Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight rating and an $18 price target. The Overweight call is based on Haduvio, the company’s extended-release formulation of nalbuphine, which is being developed as a […]",
    "url": "https://finnhub.io/api/news?id=10fad4165aae9353e88efa5db2d15164d7b55a65aa9df875fc1587b72a5daeb1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757579492,
      "headline": "Haduvio Opportunity Positions Trevi (TRVI) for Multibagger Gains, Says Morgan Stanley",
      "id": 136703972,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Trevi Therapeutics Inc. (NASDAQ:TRVI) is one of the best multibagger stocks to invest in right now. On August 21, Morgan Stanley’s Judah Frommer initiated coverage of the stock with an Overweight rating and an $18 price target. The Overweight call is based on Haduvio, the company’s extended-release formulation of nalbuphine, which is being developed as a […]",
      "url": "https://finnhub.io/api/news?id=10fad4165aae9353e88efa5db2d15164d7b55a65aa9df875fc1587b72a5daeb1"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Positive data for a pneumococcal vaccine",
    "summary": "Merck announces positive results from the STRIDE-13 Phase 3 trial evaluating Capvaxive at the ESCMID Vaccine Conference in Lisbon.The trial evaluated the safety, tolerability, and immunogenicity of...",
    "url": "https://finnhub.io/api/news?id=b5bb67925294f1db53490b23dfb073c4f2b9873c9d9a5f0725b11452b54809d0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757578582,
      "headline": "Merck: Positive data for a pneumococcal vaccine",
      "id": 136700495,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announces positive results from the STRIDE-13 Phase 3 trial evaluating Capvaxive at the ESCMID Vaccine Conference in Lisbon.The trial evaluated the safety, tolerability, and immunogenicity of...",
      "url": "https://finnhub.io/api/news?id=b5bb67925294f1db53490b23dfb073c4f2b9873c9d9a5f0725b11452b54809d0"
    }
  },
  {
    "ts": null,
    "headline": "Merck scraps £1bn London expansion as report warns UK drugs sector ‘losing out’",
    "summary": "UK pharmaceutical sector ‘risks losing investment to other countries’.",
    "url": "https://finnhub.io/api/news?id=79a69373f315cf69552812bd2539886dbc29569357d6873ceffe64444b57e4b5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757577828,
      "headline": "Merck scraps £1bn London expansion as report warns UK drugs sector ‘losing out’",
      "id": 136703973,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "UK pharmaceutical sector ‘risks losing investment to other countries’.",
      "url": "https://finnhub.io/api/news?id=79a69373f315cf69552812bd2539886dbc29569357d6873ceffe64444b57e4b5"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks Under $50 We Find Risky",
    "summary": "Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.",
    "url": "https://finnhub.io/api/news?id=db420c0eefad4aff1424c0f96f86ce266745362814610df165de8b8ba00cb4a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1757568946,
      "headline": "3 Stocks Under $50 We Find Risky",
      "id": 136703974,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.",
      "url": "https://finnhub.io/api/news?id=db420c0eefad4aff1424c0f96f86ce266745362814610df165de8b8ba00cb4a5"
    }
  }
]